Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs

Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron...

Full description

Saved in:
Bibliographic Details
Published in:Neurochemical research 2016-02, Vol.41 (1-2), p.340-352
Main Authors: Caccamo, D., Pisani, L. R., Mazzocchetti, P., Ientile, R., Calabresi, P., Pisani, F., Costa, C.
Format: Article
Language:English
Subjects:
Animals
Anticonvulsants - therapeutic use
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cell Biology
Disease Progression
Humans
Neurochemistry
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - pathology
Neurology
Neurosciences
Original Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroprotection is conceived as one of the potential tool to prevent or slow neuronal death and hence a therapeutic hope to treat neurodegenerative diseases, like Parkinson’s and Alzheimer’s diseases. Increase of oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation have been identified as main causes of neuronal death and adopted as targets to test experimentally the putative neuroprotective effects of various classes of drugs. Among these agents, antiepileptic drugs (AEDs), both the old and the newer generations, have shown to exert protective effects in different experimental models. Their mechanism of action is mediated mainly by modulating the activity of sodium, calcium and potassium channels as well as the glutamatergic and GABAergic (gamma-aminobutyric acid) synapses. Neurological pathologies in which a neuroprotective action of AEDs has been demonstrated in specific experimental models include: cerebral ischemia, Parkinson’s disease, and Alzheimer’s disease. Although the whole of experimental data indicating that neuroprotection can be achieved is remarkable and encouraging, no firm data have been produced in humans so far and, at the present time, neuroprotection still remains a challenge for the future.
ISSN:0364-3190
1573-6903
DOI:10.1007/s11064-015-1809-5